Edgar Filing: Aralez Pharmaceuticals Inc. - Form 4

Aralez Phar Form 4 April 07, 20	rmaceuticals	Inc.										
FORM	OMB APPROVAL											
CURIVI 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Number:	3235-0287				
Check this box if no longer									Expires:	January 31,		
subject		NGES IN BENEFICIAL OWNE				ERSHIP OF	Estimated a	2005 verage				
Section 16. Form 4 or				SECURITIES					burden hou			
Form 5												
obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section												
<i>See</i> Instruction 30(h) of the Investment Company Act of 1940												
1(b).												
(Print or Type	Responses)											
× • • • •	1											
				suer Name and Ticker or Trading				5. Relationship of Reporting Person(s) to				
QLT INC/	BC		Symbol					ssuer				
Aralez				alez Pharmaceuticals Inc. [ARLZ]				(Check all applicable)				
(Last)	(First)	(Middle)		of Earliest 7	Transaction							
				onth/Day/Year) /17/2016				DirectorX_ 10% Owner Officer (give title Other (specify				
SUITE 250				2010				below) below)				
	(Street)		4. If Am	nendment, D	Date Original		6	. Individual or Joi	nt/Group Filin	g(Check		
				(Month/Day/Year)				Applicable Line)				
MANGON	_X_Form filed by One Reporting Person											
VANCOU	VER, A1 V5	1 415					P	Person		1 0		
(City)	(State)	(Zip)	Tal	ble I - Non-	Derivative Sec	uritie	s Acqui	red, Disposed of,	or Beneficial	ly Owned		
1.Title of		n Date 2A. Dee	med	3.	4. Securities	-	red (A)	5. Amount of	6.	7. Nature of		
Security	(Month/Day/	Ionth/Day/Year) Execution Date			onor Disposed of			Securities Beneficially	1	Indirect Beneficial		
(Instr. 3) any (Month/Day/Year)			Code (Instr. 3, 4 and 5) (Instr. 8)				Owned		Beneficial) Ownership			
								Following Reported	or Indirect	(Instr. 4)		
						(A)		Transaction(s)	(I) (Instr. 4)			
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)				
Common	03/17/2016			S	2,400,000	D	\$	4,800,000	D			
Shares	05/1//2010			0	2,700,000	D	6.25	1,000,000	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: Aralez Pharmaceuticals Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
QLT INC/BC 887 GREAT NORTHERN WAY, SUITE 250 VANCOUVER, A1 V5T 4T5		Х					
Signatures							
/s/ Glen Ibbott Chief Financial Officer 04/	07/2016						
**Signature of Reporting Person	Date						

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.